This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
United Therapeutics Corporation
Drug Names(s): MD-0701, Treprost (Japan), treprostinil sodium, Uniprost, UT 15
Description: The major pharmacologic actions of treprostinil (a prostaglandin) are direct vasodilation of pulmonary and systemic arterial vascular beds and inhibition of platelet aggregation. In animals, the vasodilatory effects reduce right and left ventricular afterload and increase cardiac output and stroke volume.
United, Glaxo, and Pfizer
In December 1996 and January 1997, United Therapeutics obtained worldwide rights for all indications to Remodulin, from Glaxo Wellcome, Inc. and Pharmacia & Upjohn Company. The patent covering the use of treprostinil for PAH expires in the United States in October 2014 and on various dates from May 2011 to June 2014 in three other countries. Under the agreement, Glaxo is entitled to receive royalties on sales exceeding a specified threshold for a minimum period of ten years (or until expiration of the licensed patents) following the date of the first commercial sale of any product containing treprostinil.
In October 1999, United Therapeutics acquired all the outstanding stock of SynQuest, Inc., the manufacturer of treprostinil, the bulk active ingredient in Remodulin.
Pharmacia & Upjohn Company (now Pfizer) exclusively licensed to UTHR certain patents, a patent application and know-how for the composition and production of...See full deal structure in Biomedtracker
Partners: GlaxoSmithKline plc Pfizer Inc. Mochida Pharmaceutical Co., Ltd. Ascendis Pharma A/S Lee's Pharmaceutical Holdings Limited
Remodulin (injection) News
Additional information available to subscribers only: